IP Library Granted Patent US 11,612,645
Granted Patent B2
US 11,612,645 · App. 17/820,980 · Granted Mar 28, 2023

IL-15-based fusions to IL-12 and IL-18

Inventors: Warren D. Marcus (Miramar, FL); Robert Newman (Miramar, FL); Bai Liu (Cooper City, FL); Lijing You (Miramar, FL); Lin Kong (Miramar, FL); Peter Rhode (Miami, FL); Hing C. Wong (Weston, FL)
Assignee: Altor Bioscience, LLC
A61K39/00114A61K47/6811A61P35/00C07K14/54C07K14/5434C07K14/5443C07K14/715C07K16/283C12N15/62C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,612,645
App. No.
17/820,980
Granted
Mar 28, 2023
Kind
B2
Abstract

The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-12 or IL-18.

Claims (4)

1. An isolated soluble fusion protein complex comprising: a first soluble protein comprising an interleukin-15 (IL-15) polypeptide domain and a first cytokine binding polypeptide domain wherein the first cytokine binding polypeptide domain comprises a TGFβ receptor type 2 (TGFβRII), and a second soluble protein comprising, a soluble IL-15 receptor alpha sushi (IL-15RαSu) polypeptide domain and a second cytokine binding polypeptide domain wherein the second cytokine binding polypeptide domain comprises TGFβRII, wherein the IL-15 polypeptide domain binds to the IL-15RαtSu polypeptide domain to form the soluble fusion protein complex.

2. The soluble fusion protein complex of claim 1 , wherein the IL-15 polypeptide is an IL-15 variant comprising an N72D mutation (IL-15N72D).

3. The soluble fusion protein complex of claim 1 , wherein the cytokine binding polypeptide domains hind to TGFβ.

4. The soluble fusion protein complex of claim 1 , wherein the second soluble protein further comprises a biologically active polypeptide domain, and wherein the biologically active polypeptide domain comprises an immunoglobulin Fe polypeptide domain.

Assignments (4)
SECURITY INTEREST Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2022
From: MARCUS, WARREN D.; NEWMAN, ROBERT G.; LIU, BAI; YOU, LIJING; KONG, LIN; RHODE, PETER
To: ALTOR BIOSCIENCE CORPORATION
Reel/Frame 061025/0313 →
MERGER Recorded Sep 8, 2022
From: ALTOR BIOSCIENCE CORPORATION
To: ALTOR BIOSCIENCE LLC
Reel/Frame 061025/0382 →
CONSULATING AGREEMENT Recorded Sep 8, 2022
From: WONG, HING C.
To: ALTOR BIOSCIENCE LLC
Reel/Frame 061393/0760 →
Continuity (4)
Continuation 17486683 · Sep 27, 2021
Continuation 15913837 · Mar 6, 2018
Provisional Application 62467623 · Mar 6, 2017
Related Publication 20220387570A1 · Dec 8, 2022
Cited By (1)
US 12,233,116